Shorla Oncology are delighted to announce the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-depth experience in scaling oncology & specialty pharma enterprises. Nicholas Holsman will lead commercialization of novel oncology products.
Holsman has almost twenty years’ experience in leading commercial functions, with a focus on high growth start-up biotech companies. Most recently, he was Head of Commercial Operations at Oncopeptides, INC, where he was responsible for building the infrastructure to support the launch of PEPAXTO, a peptide-conjugated alkylator for the treatment of relapsed and refractory multiple myeloma patients.
Read more at: